Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Blood (2018) 132 (12): 1225–1240.

https://doi.org/10.1182/blood-2018-04-843771

Published: 2018

Includes: Supplemental data

Journal Articles

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Allison M. Winter, Daniel J. Landsburg, Anthony R. Mato, Krista Isaac, Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R. Smith, Paolo Caimi, Deepa Jagadeesh, Brian T. Hill

Blood (2017) 130 (14): 1676–1679.

https://doi.org/10.1182/blood-2017-05-786988

Published: 2017

Journal Articles

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Graham P. Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C. Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M. Beaupre, Robert Chen

Blood (2017) 129 (16): 2224–2232.

https://doi.org/10.1182/blood-2016-10-747345

Published: 2017

Includes: Supplemental data

Journal Articles

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Ariela Noy, MD PhD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, MD, Christopher Flowers, MDMS, Franck Morschhauser, Graham P. Collins, MD PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD PhD, Robert W Chen, MD

Blood (2016) 128 (22): 1213.

https://doi.org/10.1182/blood.V128.22.1213.1213

Published: 2016

Journal Articles

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Allison Marie Winter, MD, Daniel J. Landsburg, MD, Francisco J. Hernandez-Ilizaliturri, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Smith, MD, Mazyar Shadman, Paolo Caimi, MD, Deepa Jagadeesh, MD MPH, Mitchell R. Smith, Brian T. Hill, MD PhD

Blood (2016) 128 (22): 1115.

https://doi.org/10.1182/blood.V128.22.1115.1115

Published: 2016

Journal Articles

Characterisation of E. coli Lipopolysaccharide Adherence to Platelet Receptors

Dearbhla Lenehan, BSc, Alyson Murray, BSc PhD, Stephen Smith, BA PhD, Bernt Eric Uhlin, Jennifer Mitchell, BA PhD

Blood (2016) 128 (22): 4906.

https://doi.org/10.1182/blood.V128.22.4906.4906

Published: 2016

Journal Articles

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Sandra Kanan, NP, RN, MSN, Ajay K Gopal, MD, Ryan D Cassaday, MD, Andrei R. Shustov, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Mazyar Shadman, MD MPH, Warren Houston, MD PhD, Melinda Tran, Pharm.D, Oliver Press, Stephen Smith, MD

Blood (2016) 128 (22): 3577.

https://doi.org/10.1182/blood.V128.22.3577.3577

Published: 2016

Journal Articles

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Stephen Smith, Robert Dean, Matt E Kalaycio, MD, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward Copelan, John William Sweetenham

Blood (2009) 114 (22): 3325.

https://doi.org/10.1182/blood.V114.22.3325.3325

Published: 2009

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Journal Articles

Sox4 Downregulates Pu.1 Gene Expression by Binding to An Upper Regulatory Element of Pu.1, a Mechanism Contributing to Leukemogenesis.

Georg Aue, MD, Yang Du, PhD, Susan Cleveland, Stephen Smith, Utpal P. Dave, MD, Nancy Jenkins, PhD., Neal G. Copeland, PhD., Cynthia Dunbar

Blood (2009) 114 (22): 3979.

https://doi.org/10.1182/blood.V114.22.3979.3979

Published: 2009

Journal Articles

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Hien Duong, Lisa Rybicki, John Sweetenham, Brad Pohlman, Ronald Sobecks, Robert Dean, Edward Copelan, Steven Andresen, Stephen Smith, Shawnda Sungren, Josephine Chan, Brian Bolwell

Blood (2008) 112 (11): 3269.

https://doi.org/10.1182/blood.V112.11.3269.3269

Published: 2008

Journal Articles

Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide.

Robert Dean, Lisa Rybicki, Brad Pohlman, John William Sweetenham, Stephen Smith, Edward Copelan, Ronald Sobecks, Matt Kalaycio, Steven Andresen, Shawnda Sungren, Brian J. Bolwell, MD

Blood (2008) 112 (11): 2186.

https://doi.org/10.1182/blood.V112.11.2186.2186

Published: 2008

Journal Articles

Cultured CD41a+ Megakaryocytes Derived from Cord Blood CD34+ Cells Are Activated Via STAT5 but Not STAT3.

Stephen Smith, MS

Blood (2005) 106 (11): 4240.

https://doi.org/10.1182/blood.V106.11.4240.4240

Published: 2005

NARROW

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Characterisation of E. coli Lipopolysaccharide Adherence to Platelet Receptors

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Sox4 Downregulates Pu.1 Gene Expression by Binding to An Upper Regulatory Element of Pu.1, a Mechanism Contributing to Leukemogenesis.

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide.

Cultured CD41a+ Megakaryocytes Derived from Cord Blood CD34+ Cells Are Activated Via STAT5 but Not STAT3.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only